Lutetium-177-Prostate-Specific Membrane Antigen Radioligand Therapy: What Is the Value of Post-Therapeutic Imaging?

Lutetium-177-Prostate-Specific Membrane Antigen Radioligand Therapy: What Is the Value of Post-Therapeutic Imaging?

Lutetium-177 (Lu-177)-labelled radioligand therapies (RLT) targeting prostate-specific membrane antigen (PSMA) present a promising treatment for patients with progressive metastasized castration-resistant prostate cancer (mCRPC). Personalized dosimetry, facilitated by post-therapeutic imaging, offer...

Full description

Bibliographic Details
Main Author: Jules Zhang-Yin
Format: Article
Language:English
Published: MDPI AG 2024-07-01
Series:Biomedicines
Subjects:
Lutetium-177
radioligand therapies
PSMA
personalized dosimetry
post-therapeutic imaging
Online Access:https://www.mdpi.com/2227-9059/12/7/1512

Internet

https://www.mdpi.com/2227-9059/12/7/1512

Similar Items